炎症性肠病的生物治疗

Biological therapies for inflammatory bowel disease

炎症性肠病是一种慢性炎症性疾病,主要包括克罗恩病和溃疡性结肠炎,其发病原因不清楚,发病机制目前尚未完全阐明,临床治疗效果欠佳.传统的治疗在于诱导病情缓解和维持治疗,近年来炎症性肠病的治疗方案在传统方案的基础上,增加了预防与疾病本身或治疗有关的并发症、改善患者的生活质量、减少住院率及外科手术率等目的.随着生物制剂的不断出现,此目标正在逐步实现.本文对近年来新的生物制剂在炎症性肠病的临床应用进行评述.

Inflammatory bowel disease （IBD）,including Crohn＇s disease and ulcerative colitis,represents a heterogenic group of chronic diseases with a high morbidity and poor prognosis.The etiology of IBD is still unknown,and the pathogenesis of IBD has not been fully clarified.Consequently,the clinical outcome of IBD is unsatisfying.Fortunately,a variety of new biological therapies have being developed in recent years.These therapies are shown to be helpful in inducing remission,preventing complications,improving life quality of the patients,and reducing hospitalization rates and surgical rates.This article will review these new biological agents clinically used for IBD patients.